Jamie E Flerlage1, Justin N Baker1. 1. Department of Oncology, Division of Quality of Life and Palliative Care, St. Jude Children's Research Hospital , Memphis, Tennessee.
Abstract
BACKGROUND: Opioid-induced constipation (OIC) is common among children and adolescents and young adults (AYA) with progressive incurable cancer. Although methylnaltrexone is a successful treatment for OIC in adult cancer patients, no case series has established its safety and efficacy in pediatric cancer patients. OBJECTIVES: The aim of the study was to describe the safety and efficacy of methylnaltrexone use for OIC in children and AYA with progressive incurable cancer at the end of life in the inpatient and outpatient settings. METHODS: We conducted a retrospective review of medical records of children and AYA with progressive incurable cancer who received methylnaltrexone at our institution from May 2008 to June 2013. Pharmacy data were reviewed for each patient and a chart review was performed for documentation of laxation and side effects. RESULTS: Of the 9 patients (age range: 17 months to 21 years) with progressive incurable cancer who developed OIC, 7 (78%) had laxation after methylnaltrexone administration (0.15 mg/kg/dose). Of these 7 patients, 5 (71%) had laxation with the first dose, and 5 (71%) who responded had a continued response to repeated doses. The longest a patient regularly received methylnaltrexone was 9 months. Of 5 patients with intraabdominal disease, 4 (80%) had laxation. There were no negative side effects in any of the patients. Also, there was no increase in pain either qualitatively or by pain score. CONCLUSIONS: Methylnaltrexone appears to be safe and efficacious in treating OIC in children and AYA with progressive incurable cancer. Methylnaltrexone was tolerated in both the inpatient and outpatient settings and with repeated dosing.
BACKGROUND: Opioid-induced constipation (OIC) is common among children and adolescents and young adults (AYA) with progressive incurable cancer. Although methylnaltrexone is a successful treatment for OIC in adult cancerpatients, no case series has established its safety and efficacy in pediatric cancerpatients. OBJECTIVES: The aim of the study was to describe the safety and efficacy of methylnaltrexone use for OIC in children and AYA with progressive incurable cancer at the end of life in the inpatient and outpatient settings. METHODS: We conducted a retrospective review of medical records of children and AYA with progressive incurable cancer who received methylnaltrexone at our institution from May 2008 to June 2013. Pharmacy data were reviewed for each patient and a chart review was performed for documentation of laxation and side effects. RESULTS: Of the 9 patients (age range: 17 months to 21 years) with progressive incurable cancer who developed OIC, 7 (78%) had laxation after methylnaltrexone administration (0.15 mg/kg/dose). Of these 7 patients, 5 (71%) had laxation with the first dose, and 5 (71%) who responded had a continued response to repeated doses. The longest a patient regularly received methylnaltrexone was 9 months. Of 5 patients with intraabdominal disease, 4 (80%) had laxation. There were no negative side effects in any of the patients. Also, there was no increase in pain either qualitatively or by pain score. CONCLUSIONS:Methylnaltrexone appears to be safe and efficacious in treating OIC in children and AYA with progressive incurable cancer. Methylnaltrexone was tolerated in both the inpatient and outpatient settings and with repeated dosing.
Authors: J Wolfe; H E Grier; N Klar; S B Levin; J M Ellenbogen; S Salem-Schatz; E J Emanuel; J C Weeks Journal: N Engl J Med Date: 2000-02-03 Impact factor: 91.245
Authors: Jay Thomas; Sloan Karver; Gail Austin Cooney; Bruce H Chamberlain; Charles Kevin Watt; Neal E Slatkin; Nancy Stambler; Alton B Kremer; Robert J Israel Journal: N Engl J Med Date: 2008-05-29 Impact factor: 91.245
Authors: Amelia Rodrigues; Cherie Wong; Andrea Mattiussi; Sarah Alexander; Elaine Lau; L Lee Dupuis Journal: Pediatr Blood Cancer Date: 2013-06-14 Impact factor: 3.167
Authors: Veerle Piette; Kim Beernaert; Joachim Cohen; Nele S Pauwels; Anne-Lore Scherrens; Jutte van der Werff Ten Bosch; Luc Deliens Journal: Pediatr Res Date: 2020-07-09 Impact factor: 3.756